Kinnate Biopharma Inc. (KNTE) NASDAQ
$2.66 - (-)
Market Cap: $125.32M
As of 03/28/24 04:00 PM EDT. Market closed.
Kinnate Biopharma Inc. (KNTE)
NASDAQ
$2.66
- (-)
Market Cap: $125.32M
As of 03/28/24 04:00 PM EDT. Market closed.
kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other ... read more
kinnate biopharma inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors for treating genomically defined cancers. the company's lead product candidate is kin002787, which is a rapidly accelerated fibrosarcoma inhibitor that is in preclinical stage for the treatment of patients with lung cancer, melanoma, and other solid tumors. its other products in preclinical stage include kin003, which are small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors (fgfr)2 and fgfr3 genes; and small molecule research programs, including a cyclin-dependent kinase 12 inhibitor in its kin004 program. kinnate biopharma inc. was founded in 2018 and is headquartered in san diego, california. read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Williams Richard Thomas | Chief Medical Officer | Dec 01, 2023 | Option Exercise | $2.25 | 541 | 1,217 | 68,146 | Dec 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Dec 01, 2023 | Option Exercise | $2.25 | 1,459 | 3,283 | 65,593 | Dec 05, 2023, 05:00 PM |
Meltz Mark A | COO General Counsel Secretary | Dec 01, 2023 | Option Exercise | $2.25 | 541 | 1,217 | 28,136 | Dec 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Sep 01, 2023 | Option Exercise | $2.35 | 1,459 | 3,429 | 67,052 | Sep 06, 2023, 05:00 PM |
Meltz Mark A | COO General Counsel Secretary | Sep 01, 2023 | Option Exercise | $2.35 | 541 | 1,271 | 28,677 | Sep 06, 2023, 05:00 PM |
Williams Richard Thomas | Chief Medical Officer | Sep 01, 2023 | Option Exercise | $2.35 | 541 | 1,271 | 68,687 | Sep 06, 2023, 05:00 PM |
Williams Richard Thomas | Chief Medical Officer | Jun 01, 2023 | Option Exercise | $4.30 | 541 | 2,326 | 69,228 | Jun 05, 2023, 05:01 PM |
Meltz Mark A | COO General Counsel Secretary | Jun 01, 2023 | Option Exercise | $4.30 | 541 | 2,326 | 29,218 | Jun 05, 2023, 05:00 PM |
Krishnamohan Neha | Chief Financial Officer | Jun 01, 2023 | Option Exercise | $4.30 | 1,459 | 6,274 | 68,511 | Jun 05, 2023, 05:00 PM |
Tananbaum James B. | Director | May 08, 2023 | Buy | $2.80 | 1,780,000 | 4,984,000 | 3,525,957 | May 10, 2023, 05:49 PM |
Foresite Capital Management IV, LLC | 10% Owner | May 08, 2023 | Buy | $2.80 | 1,780,000 | 4,984,000 | 3,525,957 | May 10, 2023, 05:42 PM |
ORBIMED ADVISORS LLC | Director | May 04, 2023 | Buy | $2.75 | 479,909 | 1,319,750 | 4,738,453 | May 08, 2023, 05:22 PM |
ORBIMED ADVISORS LLC | Director | May 05, 2023 | Buy | $2.82 | 981,023 | 2,766,485 | 1,368,339 | May 08, 2023, 05:22 PM |
GORDON CARL L | Director | May 05, 2023 | Buy | $2.82 | 981,023 | 2,766,485 | 1,368,339 | May 08, 2023, 05:11 PM |
GORDON CARL L | Director | May 04, 2023 | Buy | $2.75 | 479,909 | 1,319,750 | 4,738,453 | May 08, 2023, 05:11 PM |
GORDON CARL L | Director | May 02, 2023 | Buy | $2.67 | 338,262 | 903,160 | 4,425,462 | May 02, 2023, 09:38 PM |
GORDON CARL L | Director | May 01, 2023 | Buy | $2.62 | 716,157 | 1,876,331 | 4,204,852 | May 02, 2023, 09:38 PM |
GORDON CARL L | Director | Apr 28, 2023 | Buy | $2.55 | 350,749 | 894,410 | 3,737,784 | May 02, 2023, 09:38 PM |
ORBIMED ADVISORS LLC | Director | May 02, 2023 | Buy | $2.67 | 338,262 | 903,160 | 4,425,462 | May 02, 2023, 09:34 PM |
ORBIMED ADVISORS LLC | Director | May 01, 2023 | Buy | $2.62 | 716,157 | 1,876,331 | 4,204,852 | May 02, 2023, 09:34 PM |
ORBIMED ADVISORS LLC | Director | Apr 28, 2023 | Buy | $2.55 | 350,749 | 894,410 | 3,737,784 | May 02, 2023, 09:34 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 01, 2023 | Option Exercise | $5.21 | 638 | 3,324 | 67,295 | Mar 03, 2023, 05:58 PM |
Meltz Mark A | COO General Counsel Secretary | Mar 01, 2023 | Option Exercise | $5.21 | 638 | 3,324 | 27,286 | Mar 03, 2023, 05:57 PM |
Krishnamohan Neha | Chief Financial Officer | Mar 01, 2023 | Option Exercise | $5.21 | 1,721 | 8,966 | 67,378 | Mar 03, 2023, 05:56 PM |
Williams Richard Thomas | Chief Medical Officer | Dec 01, 2022 | Option Exercise | $7.75 | 541 | 4,193 | 67,933 | Dec 02, 2022, 08:00 PM |
Krishnamohan Neha | Chief Financial Officer | Dec 01, 2022 | Option Exercise | $7.75 | 1,459 | 11,307 | 69,099 | Dec 02, 2022, 08:00 PM |
Meltz Mark A | COO General Counsel Secretary | Dec 01, 2022 | Option Exercise | $7.75 | 541 | 4,193 | 27,924 | Dec 02, 2022, 08:00 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 14, 2022 | Buy | $8.37 | 25,000 | 209,250 | 42,333 | Mar 15, 2022, 05:01 PM |
Williams Richard Thomas | Chief Medical Officer | Mar 11, 2022 | Buy | $8.64 | 15,000 | 129,600 | 17,333 | Mar 15, 2022, 05:01 PM |
GORDON CARL L | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:51 PM |
GORDON CARL L | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:51 PM |
GORDON CARL L | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:51 PM |
ORBIMED ADVISORS LLC | Director | Feb 15, 2022 | Buy | $9.96 | 9,000 | 89,640 | 3,509,030 | Feb 15, 2022, 09:42 PM |
ORBIMED ADVISORS LLC | Director | Feb 14, 2022 | Buy | $9.95 | 30,700 | 305,486 | 3,500,030 | Feb 15, 2022, 09:42 PM |
ORBIMED ADVISORS LLC | Director | Feb 11, 2022 | Buy | $10.22 | 156,000 | 1,594,320 | 3,469,330 | Feb 15, 2022, 09:42 PM |
Tananbaum James B. | Director | Dec 03, 2020 | Buy | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 09:39 PM |
Foresite Capital Management IV, LLC | 10% Owner | Dec 03, 2020 | Option Exercise | $20.00 | 1,000,000 | 20,000,000 | 500,000 | Dec 04, 2020, 08:57 PM |
ORBIMED ADVISORS LLC | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 06:11 PM |
GORDON CARL L | Director | Dec 02, 2020 | Buy | $20.00 | 750,000 | 15,000,000 | 450,000 | Dec 04, 2020, 05:13 PM |
Owner | Relationship | Date | Value($) |
Williams Richard Thomas | Chief Medical Officer | 12/01/2023 | 1,217 |
Krishnamohan Neha | Chief Financial Officer | 12/01/2023 | 3,283 |
Meltz Mark A | COO General Counsel Secretary | 12/01/2023 | 1,217 |
Krishnamohan Neha | Chief Financial Officer | 09/01/2023 | 3,429 |
Meltz Mark A | COO General Counsel Secretary | 09/01/2023 | 1,271 |
Williams Richard Thomas | Chief Medical Officer | 09/01/2023 | 1,271 |
Williams Richard Thomas | Chief Medical Officer | 06/01/2023 | 2,326 |
Meltz Mark A | COO General Counsel Secretary | 06/01/2023 | 2,326 |
Krishnamohan Neha | Chief Financial Officer | 06/01/2023 | 6,274 |
Tananbaum James B. | Director | 05/08/2023 | 4,984,000 |
Foresite Capital Management IV, LLC | 10% Owner | 05/08/2023 | 4,984,000 |
ORBIMED ADVISORS LLC | Director | 05/04/2023 | 1,319,750 |
ORBIMED ADVISORS LLC | Director | 05/05/2023 | 2,766,485 |
GORDON CARL L | Director | 05/05/2023 | 2,766,485 |
GORDON CARL L | Director | 05/04/2023 | 1,319,750 |
GORDON CARL L | Director | 05/02/2023 | 903,160 |
GORDON CARL L | Director | 05/01/2023 | 1,876,331 |
GORDON CARL L | Director | 04/28/2023 | 894,410 |
ORBIMED ADVISORS LLC | Director | 05/02/2023 | 903,160 |
ORBIMED ADVISORS LLC | Director | 05/01/2023 | 1,876,331 |
ORBIMED ADVISORS LLC | Director | 04/28/2023 | 894,410 |
Williams Richard Thomas | Chief Medical Officer | 03/01/2023 | 3,324 |
Meltz Mark A | COO General Counsel Secretary | 03/01/2023 | 3,324 |
Krishnamohan Neha | Chief Financial Officer | 03/01/2023 | 8,966 |
Williams Richard Thomas | Chief Medical Officer | 12/01/2022 | 4,193 |
Krishnamohan Neha | Chief Financial Officer | 12/01/2022 | 11,307 |
Meltz Mark A | COO General Counsel Secretary | 12/01/2022 | 4,193 |
Williams Richard Thomas | Chief Medical Officer | 03/14/2022 | 209,250 |
Williams Richard Thomas | Chief Medical Officer | 03/11/2022 | 129,600 |
GORDON CARL L | Director | 02/11/2022 | 1,594,320 |
GORDON CARL L | Director | 02/15/2022 | 89,640 |
GORDON CARL L | Director | 02/14/2022 | 305,486 |
ORBIMED ADVISORS LLC | Director | 02/15/2022 | 89,640 |
ORBIMED ADVISORS LLC | Director | 02/14/2022 | 305,486 |
ORBIMED ADVISORS LLC | Director | 02/11/2022 | 1,594,320 |
Tananbaum James B. | Director | 12/03/2020 | 20,000,000 |
Foresite Capital Management IV, LLC | 10% Owner | 12/03/2020 | 20,000,000 |
ORBIMED ADVISORS LLC | Director | 12/02/2020 | 15,000,000 |
GORDON CARL L | Director | 12/02/2020 | 15,000,000 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
ORBIMED ADVISORS LLC | 7,559,729 | 0.39% | -5.62% | Other |
VIKING GLOBAL INVESTORS LP | 1,820,462 | 0.02% | No change | Growth At A Reasonable Price |
BLACKROCK INC. | 586,688 | 0.00004% | -20.86% | Other |
RENAISSANCE TECHNOLOGIES LLC | 574,979 | 0.00211% | 13.64% | Other |
GEODE CAPITAL MANAGEMENT, LLC | 230,753 | 0.00006% | 4.17% | Other |
D. E. SHAW & CO., INC. | 150,695 | 0.00031% | 170.01% | Other |
Period of Report: 09/30/2023
10-K/10-Q Filings: View